SciBase Reports 74% Revenue Growth Amid Rising Losses and Strategic Expansions
Event summary
- SciBase reported a 74% increase in net sales for Q2 2026, reaching TSEK 15,308, with electrode sales volume up 118% to 40,144 units.
- The company's loss after tax widened to TSEK 28,893, while gross margin declined to 52.6% from 66.2% due to currency effects and production investments.
- SciBase submitted a 510(k) premarket notification to the FDA to expand Nevisense's U.S. indication to include Non-Melanoma Skin Cancers.
- The company reached a milestone with over 400,000 Nevisense tests sold globally and announced changes in senior management.
The big picture
SciBase's strong revenue growth reflects increasing demand for its Nevisense technology, particularly in the U.S. skin cancer market. However, the company's widening losses and declining gross margins highlight the challenges of scaling production and managing currency fluctuations. The FDA submission represents a critical strategic move to broaden Nevisense's applications, potentially unlocking new revenue streams.
What we're watching
- Regulatory Approval
- The FDA's response to SciBase's 510(k) submission will determine the company's ability to expand its U.S. market reach for Nevisense.
- Operational Efficiency
- Whether SciBase can improve its gross margin by mitigating currency effects and optimizing production costs.
- Market Expansion
- The pace at which SciBase can sustain its rapid revenue growth in key markets like the U.S. and Germany.